All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Lymphoma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View lymphoma & CLL content recommended for you

#ASCO22

Share:

Jun 3, 2022

X post image

6 Aug 2022

👀 During #ASCO22, the Lymphoma Hub spoke with Alison Moskowitz, @NorthwellHealth. We asked, What are the latest treatment advances for Hodgkin #lymphoma?

👉 https://t.co/eBDWP1YK0o 👈

#lymsm #HL

X post image

7 Jul 2022

🩺 During #ASCO22, the updated results with additional one year follow-up data on the CAPTIVATE trial in patients with #CLL/SLL were presented.

📚 Read our summary here
👉 https://t.co/Q6Kn9IIh4n 👈

#lymsm #leusm #leukemia

X post image

9 Jun 2022

📢For all our live congress coverage from #ASCO22 check out our twitter moment!

📚If you want to see more, visit the Lymphoma Hub for drug updates, articles and interviews with key opinion leaders!

⭐️ https://t.co/pkONS3yOFS ⭐️

#lymsm #lymphoma

https://t.co/dxNPlVch3P

X post image

7 Jun 2022

We hope you enjoyed following our live updates and congress coverage! 🎓

#ASCO22 was covered by us in Chicago, IL, as well as virtually!

Keep an eye on our socials for post-congress key points and insights! 📲

#medicalcongress #cancerawareness

X post image

6 Jun 2022

CONGRESS #ASCO22 | Sattva Swarup Neelapu, MD @MDAndersonNews presents data from a phase I study of ADI-001 in adult patients with R/R advanced B-cell #lymphoma.

N=6
78% AEs were of grade 1/2
ORR=67%
CR=67%

#lymsm #medicalcongress #cancerawareness

X post image

5 Jun 2022

CONGRESS #ASCO22 | Q&A: Hun Ju Lee, MD @MDAndersonNews asked about biological factors that may be contributing to the differential effect zilovertamab had in #CLL vs #MCL

A: It appears to be the complementary nature of inhibiting the BCR and ROR1 pathways together.

#lymsm

X post image

5 Jun 2022

CONGRESS #ASCO22 | Q&A @michaelwangmd @MDAndersonNews was asked if they would recommend initiation of maintenance therapy if a patient converts to MRD+ following CAR-T.

A: MRD status is not yet ready to direct therapy. Eventually, this question could be answered using big-data.

X post image

5 Jun 2022

CONGRESS #ASCO22 | Q&A @ChrisRFlowersMD, was asked about the significant drop in response rate in the crossover portion of the ROSEWOOD trial.

A: In part, we need to better understand the mechanisms of resistance in #FL, particularly in relation to single agent therapy.

#lymsm

X post image

5 Jun 2022

RT @AML_Hub: CONGRESS #ASCO22 | @fravandi1 of @MDAndersonNews presents results of a phase II study of ASTX727 + ventoclax in patients with…

X post image

4 Jun 2022

RT @gvhd_hub: CONGRESS #ASCO22 | Cole Harris Sterling @hopkinskimmel talks about PTCy for #GvHD prophylaxis in PTCL. N=65. 45% had GvHD, 2…

X post image

4 Jun 2022

CONGRESS #ASCO22 | Ryan C. Lynch, MD of @UW presents results from a clinical trial of Pola-DA-EPCH-R in patients with aggressive B-cell #NHL (N=18)

The trial met it's primary safety endpoint with only 3 dose-limiting-toxicities observed.

#lymsm #cancerawareness #medicalcongress

X post image

4 Jun 2022

CONGRESS #ASCO22 | @MarekTrnenyDr of @CharlesUniPRG presents an analysis of peripheral neuropathy using clinician- and patient-reported outcomes from the phase III POLARIX study

These findings support the use of Pola-R-CHP among patients with previously untreated #DLBCL

#lymsm

X post image

4 Jun 2022

CONGRESS #ASCO22 | @GregNowakowski of @MayoClinic @MayoHemeOnc presents data from a retrospective cohort study of tafasitamab + lenalidomide vs systemic therapy in patients with R/R #DLBCL.

The combination may improve OS in certain patients.

#medicalcongress #cancerawareness

X post image

4 Jun 2022

CONGRESS #ASCO22 | @AdamKittai of @OSUCCC_James describes racial and socioeconomic disparities among patients with #CLL

Black race was shown to be an independent prognostic variable for worse OS when controlling for the year of diagnosis and lower socioeconomic status.

#lymsm

X post image

4 Jun 2022

CONGRESS @ASCO | @falchi_lorenzo of @MSKCancerCenter presents data from the phase I/II EPCORE NHL-2 trial of epcoritamab + RCHOP in patients with high-risk #DLBCL.

N=33
ORR=100%
CMR=77%

Therapy has a manageable safety profile; no new safety signals were detected.

#ASCO22

X post image

4 Jun 2022

The @lymphomahub will be covering the following session today virtually:

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Stay tuned for live updates, key insights, and interview coverage!

#ASCO22 #medicalcongress #cancerawareness #lymsm

X post image

3 Jun 2022

CONGRESS #ASCO22 | Q&A: @ErmannMD was asked whether the worse OS for Black pts was associated with the income level. A: In multivariate analysis even adjusting for income still showed a difference in OS however this was not seen in propensity matched analysis #lymphoma #lymsm

X post image

3 Jun 2022

CONGRESS #ASCO22 | Adrienne Alise Phillips @WeillCornell asks where are we today with disparities in #lymphoma? She discusses genetic analysis that the most frequently mutated driver genes in DLBCL differ by ancestry #lymsm

X post image

3 Jun 2022

CONGRESS #ASCO22 | @DrFredLocke @MoffittNews describes outcomes by ethnicity of pts with #LBCL given axi-cel. N=1389. ORR was 74% for White, 57% for African American, 67% for Asian & 73% for Hispanic pts. AA race was associated with worse ORR & CR rate vs White #lymphoma #lymsm

X post image

3 Jun 2022

CONGRESS #ASCO22 | @ErmannMD @UofUHealth presents the differences in treatment & survival for patients with #CLL of different racial minorities. Black pts had a shorter median OS of 7.0 yrs vs white pts (9.14 years). Black pts had higher rate of comorbidities #leukemia #leusm

X post image

3 Jun 2022

CONGRESS #ASCO22 | @ErmannMD @huntsmancancer discusses racial disparities in OS in pts with #DLBCL. Compared to age-matched white pts, black pts age ≤60 had worse med OS (46 vs. 76 mos). Black race was associated with lower OS and pts were diagnosed younger #lymphoma #lymsm

X post image

3 Jun 2022

CONGRESS #ASCO22 | Q&A: Stephen Ansell @MayoClinic was asked how did Black pts on A+AVD fare vs white patients & other racial/ethnic minority groups? A: Race impacted survival with Caucasian pts doing better than other groups. Precise reason needs exploring #lymphoma #lymsm

X post image

3 Jun 2022

CONGRESS #ASCO22 | Alison J. Moskowitz @MSKCancerCenter discusses the history of NHL treatment and considers ongoing questions #lymphoma #lymsm

X post image

3 Jun 2022

CONGRESS #ASCO22 | @SharonCastelli2 @emoryhealthcare @EmoryMedicine describes AHOD1331 phase III study of children+AYA with advanced HL treated with Bv+AVE-PC vs AVE-PC. N=600. Median follow-up of 42.1 mos, 3-year EFS was 82.5% with ABVE-PC & 92.1% with Bv-AVE-PC #lymphoma #lymsm

X post image

3 Jun 2022

CONGRESS #ASCO22 | Stephen Ansell @MayoClinic reports on 6 year follow-up of the ECHELON-1 trial of pts with stage III/ IV cHL of A+AVD vs ABVD. OS favored A+AVD vs ABVD (p = 0.009). Estimated 6-year OS rates were 93.9% vs 89.4% with A+AVD vs ABVD, respectively. #lymphoma #lymsm

X post image

3 Jun 2022

CONGRESS #ASCO22 | @mike_dickinson1 @PeterMacCC was asked how patients who had been previously treated with CAR-T therapy fared versus CAR-T naïve pts? A: No difference was found in CR rates, responses seemed analogous #lymphoma #lymsm

X post image

3 Jun 2022

CONGRESS #ASCO22 | Kerry J Savage @UBC discusses the last 3 trials presented. She highlights response durability as important in the glofitamab trial. In PD-1/PDL inhibitors biomarkers of response are the key goal. SHINE supports BR + Ibr as option for NDMCL #lymphoma #lymsm

X post image

3 Jun 2022

CONGRESS #ASCO22 | @michaelwangmd @MDAndersonNews talks about the phase III SHINE trial of ibrutinib + bendamustine-rituximab +R maintenance for pts with #MCL. N=523. Median follow-up of 84.7 months. Med PFS of 80.6 months ibr + BR arm vs 52.9 mo in placebo +BR #lymphoma #lymsm

X post image

3 Jun 2022

CONGRESS #ASCO22 | Huiqiang Huang @uicc presents the data from GEMSTONE-201 evaluating an anti-PD-L1 mAb sugemalimab in R/R ENKTL. N=80 ORR was 46.2%; 29 pts achieved CR; 12-mo DoR rate was 86%. The 1- & 2-year OS rates were 68.6% and 54.6%, respectively #lymphoma #lymsm

X post image

3 Jun 2022

CONGRESS #ASCO22 | @mike_dickinson1 @PeterMacCC speaks about the results of a phase II trial of glofitamab in patients with R/R #DLBCL treated with ≥2 lines of therapy. ORR & CR rates by IRC were 51.6% & 39.4%, respectively with a median follow-up of 12.6 months #lymphoma #lymsm

X post image

3 Jun 2022

@ASCO starts today!

The Lymphoma Hub is covering ASCO virtually & in person!

The following session will be covered today:
Hematologic Malignancies-Lymphoma & Chronic Lymphocytic Leukemia

Keep an eye on our Twitter page for updates!

#ASCO22 #medicalcongress #cancerawareness

X post image

31 May 2022

The @lymphomahub will be covering the 2022 ASCO Annual Meeting!

Date: 3–7 June
Location: Hybrid

Keep an eye on our socials for live coverage throughout the day from our virtual and in-person attendance in Chicago, IL! 🗣💻

#ASCO22 #medicalcongress #cancerawareness

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ASCO 2022 American Society of Clinical Oncology

Your opinion matters

In practice, what is the most common reason you discontinue rituximab maintenance after BR in older patients with previously untreated MCL?

Newsletter

Subscribe to get the best content delivered to your inbox